NCT05702229 2026-03-18
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
AstraZeneca
Phase 2 Recruiting
Clinical Trials
14 trialsNCT06154538 2025-11-28
Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06846346 2025-11-28
GRACIE
UNICANCER
Phase 2 Recruiting
NCT06529718 2025-11-17
SEVILLA
UNICANCER
Phase 2 Recruiting
NCT04656041 2025-11-14
Folfox+Irinotecan+Chemort In Esophageal Cancer
Massachusetts General Hospital
Phase 2 Recruiting
NCT07192185 2025-09-25
Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab
Sun Yat-sen University
Phase 2 Recruiting
NCT06253611 2025-09-22
BIG
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Recruiting
NCT05024097 2025-08-27
PANTHER
Weill Medical College of Cornell University
Phase 2 Recruiting
NCT06991465 2025-05-28
Hypo-OPRA
McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase 2 Recruiting
NCT06907342 2025-05-25
COSENSE-1
St. Olavs Hospital
Phase 2 Recruiting
NCT06225843 2025-02-19
EGIA-003
Alethia Biotherapeutics
Phase 2 Recruiting
NCT06475352 2025-01-27
FUDOSE
UNICANCER
Phase 2 Recruiting
NCT05476796 2024-10-24
LOGICAN
UNICANCER
Phase 2 Recruiting
NCT06218810 2024-01-23
Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer
Fudan University
Phase 2 Recruiting